Asking how long medical patents last gets a simple answer that is almost always the wrong one.
Twenty years from filing, like any utility patent. That much is true and it is rarely what the questioner needs.
The useful answer involves two separate clocks. Patent term, which can be extended for regulatory delay, and regulatory exclusivity, which is granted by the FDA and runs independently.
Effective protection ends at the later of the two, and modelling only one is the most common error in this area.
The two clocks
| Protection | Granted by | Runs from |
|---|---|---|
| Patent term | USPTO | Filing date, 20 years |
| Patent Term Adjustment | USPTO | Added for USPTO delay |
| Patent Term Extension | USPTO, on FDA data | Added for regulatory review |
| Regulatory exclusivity | FDA | Approval date |
These are independent. A drug can be protected by exclusivity after its patents expire, or by patents long after exclusivity ends.
Neither is a substitute for the other. Exclusivity blocks competing approvals; patents block practising the invention.
Why the term needs extending
FDA review consumes patent term while the product cannot be sold.
| Stage | Typical duration | Term consumed |
|---|---|---|
| Compound or device patented | Year 0 | — |
| Preclinical work | 2–4 years | Yes |
| Clinical trials | 4–7 years | Yes |
| FDA review | 1–2 years | Yes |
| Approval | Year 8–13 | — |
| Marketing | Whatever remains | The only revenue period |
A compound filed in 2012 and approved in 2023 has eight years left of a twenty-year term to recover the cost of everything before it.
Patent Term Extension addresses exactly that gap, and only that gap. See patent term extension.
How the extension is calculated
| Component | Amount |
|---|---|
| Testing phase | Half of it |
| Review phase | All of it |
| Less any applicant delay | Deducted |
| Maximum | 5 years |
| Overall cap | 14 years of remaining term from approval |
| Patents extendable per product | One |
The fourteen-year cap frequently binds before the five-year maximum does. A product approved with twelve years of term remaining can receive only two years, regardless of how long review took.
Only one patent per product may be extended, so sponsors choose — usually the composition patent, because it is the strongest and expires earliest.
The application deadline is sixty days from approval and missing it forfeits the extension entirely.
Devices are mostly different
| Pathway | Extension available? | Share of devices |
|---|---|---|
| 510(k) clearance | No | The great majority |
| Premarket approval (PMA) | Yes | High-risk Class III only |
| De novo | Limited | Small |
| Exempt | No | Low-risk |
Most medical device patents run the ordinary twenty years, because most devices clear through 510(k) and that pathway does not qualify for extension.
Device patents also face a different commercial reality. Product cycles are shorter, so a device patent frequently outlives the product it covers — which shows up as early abandonment at a maintenance fee.
What happens between grant and approval
A medical patent frequently grants years before the product is approved.
| Year | Event | Patent position |
|---|---|---|
| 0 | Filed | Term starts |
| 4 | Granted | In force, no revenue |
| 4–11 | Trials and review | First maintenance fee falls due |
| 7.5 | Second fee | Still no revenue |
| 11 | Approval | Revenue begins |
| 11 | PTE application, 60-day deadline | — |
The first two maintenance fees are frequently paid before any revenue exists, which is unusual and worth budgeting for.
Missing one during that period ends everything, including the extension that has not yet been applied for.
Regulatory exclusivity periods
| Exclusivity | Length | Applies to |
|---|---|---|
| New chemical entity | 5 years | First approval of a new active moiety |
| New clinical investigation | 3 years | New indication or formulation with new trials |
| Orphan drug | 7 years | Designated rare disease indications |
| Biologics | 12 years | Reference biological products |
| Paediatric | +6 months | Added to existing periods |
| Generic first-filer | 180 days | The first successful Paragraph IV filer |
Biologics exclusivity is the longest in the system and applies regardless of patents entirely.
Paediatric exclusivity is additive, which is why sponsors conduct paediatric studies — six months added to every existing period on the product.
Orphan exclusivity is indication-specific. It blocks approval for the designated rare disease, not for other uses of the same compound.
Worked example: two products
A small-molecule drug
| Event | Date |
|---|---|
| Composition patent filed | 2012 |
| Ordinary expiry | 2032 |
| FDA approval | 2023 |
| PTE awarded | +3.5 years |
| Extended patent expiry | 2035.5 |
| NCE exclusivity ends | 2028 |
| Paediatric adds | +6 months → 2028.5 |
| Effective protection ends | 2035.5 — the patent |
The patent outlasts the exclusivity here, so exclusivity never becomes the binding constraint.
A Class II device
| Event | Date |
|---|---|
| Patent filed | 2016 |
| 510(k) clearance | 2019 |
| PTE available? | No — wrong pathway |
| Ordinary expiry | 2036 |
| Regulatory exclusivity | None applicable |
| Effective protection ends | 2036 — the patent, unextended |
| Product likely discontinued by | ~2027 |
No extension, no exclusivity, ordinary term. The complexity that surrounds drug patents does not apply.
And the patent will probably outlive the product. Which is why device patents frequently lapse at a fee window — the invention is no longer sold. See the patent survival curve.
Maintenance fees still apply
| Fee | Due after grant | Large entity |
|---|---|---|
| First | 3.5 years | $2,150 |
| Second | 7.5 years | $4,040 |
| Third | 11.5 years | $8,280 |
| Total | $14,470 |
An extension applies only to a patent still in force. Missing a maintenance fee ends the patent regardless of any extension awarded or exclusivity running.
This matters more than it sounds for medical patents, because grant frequently precedes approval by years. A patent granted in 2018 and approved in 2023 has already faced its first fee before generating any revenue.
| Ipiry Patent Survival Curve v1.0 | Rate |
|---|---|
| Survive the 3.5-year fee (2022 cohort) | 85.8% |
| Survive the 7.5-year fee (2018 cohort) | 64.6% |
| Reach full term (2014 cohort) | 41.4% |
| Abandoned before full term | 58.6% |
Computed from 27,273,654 USPTO maintenance fee records covering 8,262,336 US utility patents.
Diligence during review
| Factor | Effect on the extension |
|---|---|
| Regulatory review time | Adds to the extension |
| Applicant delay during review | Deducted |
| Failure to act with due diligence | Deducted |
| Testing phase | Half counted |
| Time before the patent granted | Not counted |
Applicant delay reduces the award. Periods where the sponsor was not pursuing approval with due diligence are subtracted from the calculation.
Which means regulatory strategy affects patent term directly. Slow responses to FDA information requests cost extension days, and the connection is not obvious from either side of the organisation.
Orange Book listing decisions
| Patent | Listable? |
|---|---|
| Drug substance | Yes |
| Drug product formulation | Yes |
| Approved method of use | Yes, per indication |
| Manufacturing process | No |
| Device component of a combination | Depends |
Listing determines whether a generic must address the patent in its application, which is what creates the Paragraph IV mechanism and the 30-month stay.
Process patents cannot be listed, so they protect against practising the process without shaping the generic approval timeline at all.
The patent cliff
| Stage | What happens |
|---|---|
| Protection ends | Generic or biosimilar entry becomes possible |
| Small molecules | Rapid price erosion, often steep within a year |
| Biologics | Slower — manufacturing and substitution barriers |
| Devices | Competitive, less abrupt |
Small molecules and biologics behave differently after expiry, which is why the twelve-year biologics exclusivity matters less than it might appear and more than it might appear at the same time.
Generic entry requires an approved application, not just an expired patent. The first successful Paragraph IV filer gets 180 days of exclusivity, which shapes the timing of the whole cliff.
Which means the expiry date and the entry date are different questions.
Multiple patents, different dates
| Patent type | Filed | Expires | Extendable |
|---|---|---|---|
| Composition of matter | At discovery | Earliest | Usually the one chosen |
| Formulation | During development | Later | Only if chosen instead |
| Method of treatment | As indications emerge | Later | Same |
| Process | During scale-up | Later | Same |
| Device design | Late | 15 yrs from grant | No |
The composition patent expires first and is strongest, which is why it is normally the one extended.
Later patents expire later and cover less. They shape what a competitor can launch rather than whether one launches at all. See patents on pharmaceutical drugs.
Method-of-treatment patents
| Feature | Effect |
|---|---|
| Claims | A method of treating a condition with the compound |
| Filed | As indications emerge, often years after the compound |
| Expires | Later than the composition patent |
| Covers | The use, not the substance |
| Generic workaround | Skinny labelling — omit the patented indication |
Method patents outlive composition patents and cover less. A generic that omits the patented indication from its label may launch for the other approved uses.
Which is why the composition patent is normally the one extended. It is the one that actually blocks entry.
Method patents shape what a competitor can market, not whether one enters at all.
Outside the US
| Jurisdiction | Extension mechanism |
|---|---|
| United States | Patent Term Extension |
| Europe | Supplementary Protection Certificate, per country |
| Japan | Patent term extension system |
| Korea | Extension system |
| Most others | None |
Rights are national and so are extensions. A global protection timeline has to be built jurisdiction by jurisdiction, because the calculations, maximums and qualifying pathways all differ.
SPCs are granted country by country in Europe, which means a European family can have different effective expiry dates in different member states.
Combination products
| Component | Protection | Clock |
|---|---|---|
| The drug | Composition patent + NCE exclusivity | Earliest expiry |
| The delivery device | Utility patent, possibly PMA | Separate |
| The device appearance | Design patent, 15 yrs from grant, no fees | Separate |
| The formulation | Later utility patent | Later |
A prefilled autoinjector has at least three protection clocks running. They start at different times and end at different times.
Extension applies to one patent for the approved product, so a combination product still gets only one PTE.
Which means the timeline has to be built asset by asset, not for the product as a single thing. See how long are design patents good for.
Practical timeline questions
| Question | Where the answer is |
|---|---|
| When does the composition patent expire? | Front page + PTA + PTE |
| Is any exclusivity still running? | Orange Book |
| Has the patent been challenged? | PTAB and court records |
| Are fees current? | Patent Center |
| What about Europe? | SPC records per country |
Five sources, and skipping any one produces a confident wrong date.
Term adjustment still applies
| Mechanism | Effect |
|---|---|
| Patent Term Adjustment | Days restored for USPTO delay |
| Patent Term Extension | Time restored for FDA delay |
| Both on one patent | Possible |
| Terminal disclaimer | Can cap the result |
PTA and PTE are separate and can both apply. A patent delayed in examination and then delayed in regulatory review can receive both, which is easy to miss when calculating expiry from the front page alone.
A terminal disclaimer overrides. Where one was filed, the capped date governs regardless of adjustments earned.
Checking a specific product
| Step | Where |
|---|---|
| 1. Patents and exclusivities declared | FDA Orange Book |
| 2. Patent numbers from the listing | Orange Book entry |
| 3. Claims, filing date, PTA, PTE | Google Patents or Patent Public Search |
| 4. Maintenance fee status | USPTO Patent Center |
| 5. Generic applications and litigation | FDA records, court dockets |
The Orange Book is the starting point because it lists what the sponsor declared for that product.
It does not update automatically. A listed patent may have expired, been invalidated or been narrowed since listing, so cross-check each one.
How long do medical patents last: the checklist
- Do not use twenty years from filing as the answer. It is technically right and practically wrong.
- Model both clocks — patent term and regulatory exclusivity — and take the later.
- Check whether the product qualifies for extension. Most devices do not.
- Apply for PTE within sixty days of approval. The deadline is unextendable.
- Choose which patent to extend deliberately. Only one per product.
- Remember the fourteen-year cap frequently binds before the five-year maximum.
- Check regulatory exclusivity separately — NCE, orphan, paediatric, biologics.
- Keep paying maintenance fees. An extension on a lapsed patent is worthless.
- Build foreign timelines jurisdiction by jurisdiction. SPCs differ per country.
- Start from the Orange Book for any specific product, then verify each patent directly.